Link Silicon Valley
The fastest way to connect to the people, companies and capital of Silicon Valley
Free 30 Day Trial Account
Sign Up | Log In
My Lists

Osprey Pharmaceuticals USA  Acquired by CoMentis (2006  amount undisclosed )

San Francisco, CA
Website Company Summary Management Team

CEO: Jack M Anthony (04/30/2007)
President/COO/Operations: John R McDonald (1998)
General Management: Laura McIntosh (10/31/2005) ; Hongsheng Su (09/30/2005)
Former Employees: Barbara K Finck Susan Wilson

Outside board: (May no longer be on the board) John E Hamer (Burrill & Company) Martial LacroixJean-Francois Pariseau (BDC Venture Capital);  Nassim Usman (Catalyst Biosciences President/CEO)

Business description: Osprey Pharmaceuticals USA (OPUS) is a clinical stage company focused on the development of novel protein therapeutics for the treatment of inflammatory and immune diseases. The company is advancing a pipeline of proprietary fusion protein therapeutics known as Leukocyte Population Modulators (LPMs) that are designed to selectively target and neutralize chemokine-activated leukocytes underlying a variety of inflammatory and immune diseases. The Company’s lead candidate, CCL2-LPM targeting the CCR2 chemokine receptor expressed by certain pathologically activated leukocytes is in a Phase Ib clinical trial for the treatment of IgA nephropathy. The company has developed a powerful chemokine-based protein therapeutic platform based on our pioneering insight into the chemokine system, a complex network of chemokine molecules (ligands) and receptors that regulate cell migration and inflammatory immune responses. Each of our novel protein therapeutics is designed to target a specific chemokine receptor, thereby blocking the inappropriate immune system cascade underlying a given disease.

Rounds: 2
Recent Fundings: May 2009   Jun 2008
Capital raised: 17.2M
Last Round: 6.2M
Ownership: Acquired by CoMentis (2006  amount undisclosed )
VCs include: BurrillAndCompany;  BDC Venture Capital;  Yasuda Enterprise Development;  Business Development Bank of Canada;  GeneChem Therapeutics Venture Fund;  Novo Nordisk Biotech Fund;  Western Technology Seed Investment Fund

Last Tweets


Last Mentions

Record updated: Aug 2009
Sector: Biotech
Year Founded: 2008
Rounds: 2
Recent Fundings: May 2009   Jun 2008
Capital Raised: 17.2M
Last Round: 6.2M
Ownership: Acquired by CoMentis (2006  amount undisclosed )